Recce Pharmaceuticals Ltd Receives AUD $3.7M Tax Refund
Key points
- AUD $3.7M income tax refund received from ATO
- Includes overseas R&D expenditure and interest
- Pro-forma cash position now AUD $33.1 million
- Expecting further non-dilutive funds
Full summary
Recce Pharmaceuticals Ltd, a developer of synthetic anti-infectives, announced the receipt of an AUD $3.7M income tax refund from the Australian Taxation Office (ATO) for the financial year ending 30 June 2025. The refund includes AUD $3.57M from overseas R&D expenditure and AUD $95.8K in interest. This influx of funds extends the company's pro-forma cash position to AUD $33.1M, well-positioned for upcoming Phase 3 clinical trial milestones. The company anticipates further non-dilutive funds and is looking to receive an AUD $7.5M R&D Tax Incentive rebate for FY2026. The announcement follows a recent placement raising AUD $4.0M and an upcoming Share Purchase Plan to raise an additional AUD $4.0M.
Guidance
Recce Pharmaceuticals Ltd expects a pro-forma cash position of AUD $33.1M
Outlook
The company is well-positioned to achieve upcoming Phase 3 clinical trial milestones and expects further non-dilutive funds.
Summary generated by a large language model. Please interpret with care.